MSD is paying $20m upfront to activate an alliance with Flagship’s Quotient Therapeutics to find new targets in inflammatory bowel disease.
Otsuka buys Transcend Therapeutics for $700M upfront
Otsuka is buying neuropsychiatric drugmaker Transcend Therapeutics in a deal worth roughly $1.2 billion, further bolstering a class of drugs that are supposed to provide


